Louise Chen
Stock Analyst at Cantor Fitzgerald
(0)
# 3246
Out of 5,240 analysts
325
Total ratings
33.95%
Success rate
2.96%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Spero Therapeutics | Reiterates: Overweight | n/a | n/a | n/a | 5 | Nov 15, 2024 | |
Novo Nordisk | Reiterates: Overweight | 160 160 | 81.21 | 97.02% | 20 | Nov 6, 2024 | |
Vaxcyte | Reiterates: Overweight | n/a | n/a | n/a | 6 | Nov 6, 2024 | |
Pfizer | Reiterates: Overweight | 45 45 | 26.41 | 70.39% | 30 | Oct 25, 2024 | |
Zai Lab | Reiterates: Overweight | n/a | n/a | n/a | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 215 215 | 144.67 | 48.61% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 155 155 | 99.64 | 55.56% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 885 885 | 743.02 | 19.11% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 200 200 | 175.46 | 13.99% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 925 925 | 690.23 | 34.01% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 10.45 | 522.01% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 | n/a | n/a | 4 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 | 1.05 | 376.19% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 | 1.04 | 2303.85% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 | 15 | 233.33% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 | n/a | n/a | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 | 13.27 | 276.79% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 18 1 | n/a | n/a | 7 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 5 | 1 | 400% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 5 9 | 2.71 | 232.1% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 33 21 | 0.4 | 5150% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 1 | n/a | n/a | 3 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1200 80 | n/a | n/a | 2 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 2 | n/a | n/a | 2 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 6 | n/a | n/a | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | n/a | n/a | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 1250 | n/a | n/a | 1 | Sep 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 67500 | 0.89 | 7584169.66% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | n/a | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 23 | n/a | n/a | 2 | May 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 240 258 | 453.85 | -43.15% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 9 15 | 21 | -28.57% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 18 | n/a | n/a | 3 | Oct 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 50 | 1.47 | 3301.36% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 0 | n/a | n/a | 3 | May 7, 2018 |